Market Overview:
The global cellular tumor antigen p53 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising awareness about early diagnosis and treatment of cancer, and technological advancements in the field of cancer diagnostics. Based on type, the global cellular tumor antigen p53 market is segmented into COTI-2, D-12PGJ3, APR-246, ATRN-502, Cenersen Sodium (CAS: 914078-62-1), MJ - 05 (CAS: 870909 - 95 - 2), MX 225 (CAS: 1264970 - 97 – 4) and others. Based on application, the global cellular tumor antigen p53 market is segmented into ovarian cancer detection & treatment; prostate cancer detection & treatment; brain tumors detection & treatment; lung cancers detection &treatment ; leukemia/lymphoma cancers detection&treatment ; other solid tumors detections& treatments . In terms of region , North America dominates the global cellular tumor antigen p53 market followed by Europe .
Product Definition:
Cellular tumor antigen p53, also known as tumor protein p53 or TP53, is a protein that in humans is encoded by the TP53 gene. The TP53 gene encodes a nuclear phosphoprotein that regulates the cell cycle and apoptosis. The protein encoded by this gene is a transcription factor that binds to DNA sequences known as promoters. It regulates genes involved in cell cycle arrest, DNA repair, apoptosis, and senescence. This protein forms complexes with other proteins, including histone deacetylases (HDACs) and mediates repression of target genes.
COTI-2:
Cotellic Oligomerization-2 (COTI-2) is a protein that in humans is encoded by the COTM gene. It belongs to the family of death receptor-activating proteins and shares similar structural characteristics with other members of this family such as Bcl-2, Bcl-xL, Bad, and Bak.
D-12PGJ3:
D-12PGJ3 is a selective inhibitor of 12-O-phosphatidylserine, which is an important intracellular signaling molecule in the p53 tumor suppressor pathway. Inhibition of D-12PGJ3 by Chimeric Antigen Receptor (CAR)-T cell therapy results in activation and recruitment of immune cells to the site of tumor development, ultimately leading to its destruction.
Application Insights:
The others segment held the largest share of the global cellular tumor antigen p53 market in 2017. This is due to a large number of products under this category, which includes lung cancer, breast cancer and others. Among these other types of cancers, brain cancer accounted for the maximum share in 2017 owing to an increase in incidence rates over other types of cancers. According to data published by WHO, worldwide around 60-80% people develop some form of brain tumor during their lifetime and around 17 million people are diagnosed with a brain tumor every year making it one of the most common reasons for neurological disorders globally.
Ovarian Cancer was estimated as one of the major applications for GCTA p53 drug across all regions including North America, Europe, Asia Pacific and Middle East & Africa countries.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high R&D investment by companies and increased focus on drug development for cancer treatment. The region is expected to maintain its dominance throughout the forecast period owing to constant technological advancements and increasing demand for highly effective treatment methods for cancer patients.
The key countries considered while analyzing this study were China, Japan, South Korea, Australia.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the cellular tumor antigen p53 market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths from cancer worldwide. This number is expected to increase to 21 million new cases and 13 million deaths by 2030. This will create a large demand for cellular tumor antigen p53 products, which will drive the growth of this market.
- Rising awareness about early detection and treatment: There is an increasing awareness among people about early detection and treatment of cancers, which is driving the demand for cellular tumor antigen p53 products. People are becoming more aware about the benefits of early diagnosis and treatment, which is helping to drive the growth of this market.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cellular Tumor Antigen p53 Market Research Report
By Type
COTI-2, D-12PGJ3, APR-246, ATRN-502, Cenersen Sodium, MJ-05, MX-225, Others
By Application
Ovarian Cancer, Prostate Cancer, Brain Cancer, Others
By Companies
Advaxis, Inc., American Gene Technologies International Inc., Aprea AB, Cellceutix Corporation, Critical Outcome Technologies Inc., Eleos Inc., ORCA Therapeutics B.V., OSE Pharma SA, PCI Biotech Holding ASA, Quark Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Shenzen SiBiono GeneTech Co., Ltd., SK Biopharmaceuticals Co., Ltd., Tara Immuno-Oncology Therapeutics LLC, Z53 Therapeutics, LLC
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
166
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Cellular Tumor Antigen p53 Market Report Segments:
The global Cellular Tumor Antigen p53 market is segmented on the basis of:
Types
COTI-2, D-12PGJ3, APR-246, ATRN-502, Cenersen Sodium, MJ-05, MX-225, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ovarian Cancer, Prostate Cancer, Brain Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Advaxis, Inc.
- American Gene Technologies International Inc.
- Aprea AB
- Cellceutix Corporation
- Critical Outcome Technologies Inc.
- Eleos Inc.
- ORCA Therapeutics B.V.
- OSE Pharma SA
- PCI Biotech Holding ASA
- Quark Pharmaceuticals, Inc.
- Stemline Therapeutics, Inc.
- Shenzen SiBiono GeneTech Co., Ltd.
- SK Biopharmaceuticals Co., Ltd.
- Tara Immuno-Oncology Therapeutics LLC
- Z53 Therapeutics, LLC
Highlights of The Cellular Tumor Antigen p53 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- COTI-2
- D-12PGJ3
- APR-246
- ATRN-502
- Cenersen Sodium
- MJ-05
- MX-225
- Others
- By Application:
- Ovarian Cancer
- Prostate Cancer
- Brain Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cellular Tumor Antigen p53 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
p53 is a tumor suppressor gene that helps to prevent the growth of tumors. When p53 is damaged or deleted, it can allow tumors to grow and spread.
Some of the major players in the cellular tumor antigen p53 market are Advaxis, Inc., American Gene Technologies International Inc., Aprea AB, Cellceutix Corporation, Critical Outcome Technologies Inc., Eleos Inc., ORCA Therapeutics B.V., OSE Pharma SA, PCI Biotech Holding ASA, Quark Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Shenzen SiBiono GeneTech Co., Ltd., SK Biopharmaceuticals Co., Ltd., Tara Immuno-Oncology Therapeutics LLC, Z53 Therapeutics, LLC.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cellular Tumor Antigen p53 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cellular Tumor Antigen p53 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cellular Tumor Antigen p53 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cellular Tumor Antigen p53 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cellular Tumor Antigen p53 Market Size & Forecast, 2018-2028
4.5.1 Cellular Tumor Antigen p53 Market Size and Y-o-Y Growth
4.5.2 Cellular Tumor Antigen p53 Market Absolute $ Opportunity
Chapter 5 Global Cellular Tumor Antigen p53 Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cellular Tumor Antigen p53 Market Size Forecast by Type
5.2.1 COTI-2
5.2.2 D-12PGJ3
5.2.3 APR-246
5.2.4 ATRN-502
5.2.5 Cenersen Sodium
5.2.6 MJ-05
5.2.7 MX-225
5.2.8 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cellular Tumor Antigen p53 Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cellular Tumor Antigen p53 Market Size Forecast by Applications
6.2.1 Ovarian Cancer
6.2.2 Prostate Cancer
6.2.3 Brain Cancer
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cellular Tumor Antigen p53 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cellular Tumor Antigen p53 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cellular Tumor Antigen p53 Analysis and Forecast
9.1 Introduction
9.2 North America Cellular Tumor Antigen p53 Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cellular Tumor Antigen p53 Market Size Forecast by Type
9.6.1 COTI-2
9.6.2 D-12PGJ3
9.6.3 APR-246
9.6.4 ATRN-502
9.6.5 Cenersen Sodium
9.6.6 MJ-05
9.6.7 MX-225
9.6.8 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cellular Tumor Antigen p53 Market Size Forecast by Applications
9.10.1 Ovarian Cancer
9.10.2 Prostate Cancer
9.10.3 Brain Cancer
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cellular Tumor Antigen p53 Analysis and Forecast
10.1 Introduction
10.2 Europe Cellular Tumor Antigen p53 Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cellular Tumor Antigen p53 Market Size Forecast by Type
10.6.1 COTI-2
10.6.2 D-12PGJ3
10.6.3 APR-246
10.6.4 ATRN-502
10.6.5 Cenersen Sodium
10.6.6 MJ-05
10.6.7 MX-225
10.6.8 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cellular Tumor Antigen p53 Market Size Forecast by Applications
10.10.1 Ovarian Cancer
10.10.2 Prostate Cancer
10.10.3 Brain Cancer
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cellular Tumor Antigen p53 Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cellular Tumor Antigen p53 Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cellular Tumor Antigen p53 Market Size Forecast by Type
11.6.1 COTI-2
11.6.2 D-12PGJ3
11.6.3 APR-246
11.6.4 ATRN-502
11.6.5 Cenersen Sodium
11.6.6 MJ-05
11.6.7 MX-225
11.6.8 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cellular Tumor Antigen p53 Market Size Forecast by Applications
11.10.1 Ovarian Cancer
11.10.2 Prostate Cancer
11.10.3 Brain Cancer
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cellular Tumor Antigen p53 Analysis and Forecast
12.1 Introduction
12.2 Latin America Cellular Tumor Antigen p53 Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cellular Tumor Antigen p53 Market Size Forecast by Type
12.6.1 COTI-2
12.6.2 D-12PGJ3
12.6.3 APR-246
12.6.4 ATRN-502
12.6.5 Cenersen Sodium
12.6.6 MJ-05
12.6.7 MX-225
12.6.8 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cellular Tumor Antigen p53 Market Size Forecast by Applications
12.10.1 Ovarian Cancer
12.10.2 Prostate Cancer
12.10.3 Brain Cancer
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cellular Tumor Antigen p53 Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cellular Tumor Antigen p53 Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cellular Tumor Antigen p53 Market Size Forecast by Type
13.6.1 COTI-2
13.6.2 D-12PGJ3
13.6.3 APR-246
13.6.4 ATRN-502
13.6.5 Cenersen Sodium
13.6.6 MJ-05
13.6.7 MX-225
13.6.8 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cellular Tumor Antigen p53 Market Size Forecast by Applications
13.10.1 Ovarian Cancer
13.10.2 Prostate Cancer
13.10.3 Brain Cancer
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cellular Tumor Antigen p53 Market: Competitive Dashboard
14.2 Global Cellular Tumor Antigen p53 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Advaxis, Inc.
14.3.2 American Gene Technologies International Inc.
14.3.3 Aprea AB
14.3.4 Cellceutix Corporation
14.3.5 Critical Outcome Technologies Inc.
14.3.6 Eleos Inc.
14.3.7 ORCA Therapeutics B.V.
14.3.8 OSE Pharma SA
14.3.9 PCI Biotech Holding ASA
14.3.10 Quark Pharmaceuticals, Inc.
14.3.11 Stemline Therapeutics, Inc.
14.3.12 Shenzen SiBiono GeneTech Co., Ltd.
14.3.13 SK Biopharmaceuticals Co., Ltd.
14.3.14 Tara Immuno-Oncology Therapeutics LLC
14.3.15 Z53 Therapeutics, LLC
